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Splice-site mutations in the beta-globin gene can lead to aberrant
transcripts and decreased functional beta-globin, causing beta-
thalassemia. Triplex-forming DNA oligonucleotides (TFOs) and
peptide nucleic acids (PNAs) have been shown to stimulate recom-
bination in reporter gene loci in mammalian cells via site-specific
binding and creation of altered helical structures that provoke DNA
repair. We have designed a series of triplex-forming PNAs that can
specifically bind to sequences in the human beta-globin gene. We
demonstrate here that these PNAs, when cotransfected with re-
combinatory donor DNA fragments, can promote single base-pair
modification at the start of the second intron of the beta-globin
gene, the site of a common thalassemia-associated mutation. This
single base pair change was detected by the restoration of proper
splicing of transcripts produced from a green fluorescent protein-
beta-globin fusion gene. The ability of these PNAs to induce
recombination was dependent on dose, sequence, cell-cycle stage,
and the presence of a homologous donor DNA molecule. Enhanced
recombination, with frequencies up to 0.4%, was observed with
use of the lysomotropic agent chloroquine. Finally, we demon-
strate that these PNAs were effective in stimulating the modifica-
tion of the endogenous beta-globin locus in human cells, including
primary hematopoietic progenitor cells. This work suggests that
PNAs can be effective tools to induce heritable, site-specific mod-
ification of disease-related genes in human cells.
beta-thalassemia  gene correction  triplex-forming oligonucleotides 
gene targeting
Mutations in the beta-globin gene that affect any stage inbeta-globin biogenesis can cause beta-thalassemia. Identified
mutations include single base pair changes that lead to frameshift
mutations or changes in canonical sequences that affect mRNA
stability and processing (1). As monogenic disorders, beta-
thalassemia and sickle cell anemia have attracted substantial efforts
directed at gene therapy by gene replacement, and there has been
ongoing progress in this regard. In one approach specific to the
thalassemias in which the genetic defect affects mRNA splicing,
antisense oligonucleotides have been used to manipulate the splice
site choice in beta-globin premRNA to prevent aberrant splicing.
Restoration of proper beta-globin splicing has been demonstrated
in human erythroid cells derived from beta-thalassemic patients,
and in transgenic mouse models containing splicing mutations in
the beta-globin gene (2, 3).
In this study, we use an antigene approach to correct a thalas-
semia-causing splice-site mutation at the level of chromosomal
DNA in cultured cells, generating heritable, site-specific modifica-
tion of the beta-globin gene. We have used peptide nucleic acids
(PNAs), a class of triplex-forming molecules shown to be effective
at provoking recombination and repair at chromosomal sites near
PNA binding sites (4). PNAs contain standard nucleobases linked
to a peptide-like backbone, and their advantages include resistance
to nucleases and proteases, and increased stability of the PNA/DNA
duplex compared with DNA/DNA. PNAs can bind DNA by strand
invasion into the duplex, forming a so-called ‘‘D-loop’’ (5, 6). At
homopurine/homopyrimidine stretches, the purine strand of the
DNA duplex can be bound by two PNAs linked together (bis-PNA)
to form a PNA/DNA/PNA triplex. One PNA segment of the
bis-PNA serves as the Watson–Crick complementary strand to the
purine strand of the target site, whereas the other PNA employs
Hoogsteen bonding to the newly formed DNA/PNA duplex to form
a PNA/DNA/PNA structure. There has been considerable interest
in bis-PNAs both in antisense and antigene applications (4, 7–10).
A common beta-thalassemia mutation occurs at the first position
of intron 2 in the human beta-globin gene (designated IVS2–1). A
G3A mutation at this position disrupts normal splicing and causes
thalassemia. We have identified several polypurine sequences in the
vicinity of the IVS2–1 mutation that would be suitable sites for
bis-PNA-mediated triple-helix formation. To test the ability of
bis-PNAs to induce recombination and thereby direct sequence
change at the IVS2–1 position of the beta-globin gene, we have
designed a cellular assay that allows quantification of site-specific
gene modification at IVS2–1. In this assay, IVS2 has been inserted
into the green fluorescent protein (GFP) gene, such that GFP
expression requires correct IVS2 splicing. Cells were engineered to
contain a single copy of this GFP/IVS2 fusion gene with a G3A
mutation at IVS2–1 that abrogates GFP fluorescence. GFP fluo-
rescence can be restored by bis-PNA-stimulated correction of this
G3A mutation by homologous recombination.
We report here that bis-PNA binding at homopurine sites within
the IVS2 sequence can stimulate correction of the beta-globin
IVS2–1 G3A mutation by short (51 nt) single-stranded donor
DNAs in our cellular assay. The gene correction is shown to be
stimulated by bis-PNAs designed to bind 35, 64, 194, 512, and 830
base pairs away from the position of the splice-site mutation. We
also show that the gene correction is influenced by cell cycle phase,
with the highest activity observed in cells in S phase. Finally, we
demonstrate that bis-PNAs can provoke targeted modification
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within the endogenous beta-globin locus in human cells, including
human primary hematopoietic progenitor cells, highlighting the
potential of these DNA-reactive molecules to provoke heritable
and long-term changes at disease-related sites in the human ge-
nome. To our knowledge, this demonstration of endogenous gene
modification in human CD34 cells using bis-PNAs has been
previously undescribed.
Results
Development of Cellular Assay to Quantify Gene Conversion in the
Beta-Globin Gene. To quantify the ability of PNAs to induce gene
correction at the human beta-globin locus, we generated a Chinese
hamster ovary (CHO) reporter cell line containing a single copy of
the GFP gene interrupted by the second intron of the human
beta-globin gene, such that GFP expression requires proper splicing
of this intronic sequence (8). A G3A mutation at position 1 of this
intron (GFP/IVS2–1G3A) abolishes the normal donor splice site
while activating a cryptic splice site, resulting in a GFP mRNA that
retains an additional 47 nt of intron and yields no GFP protein
expression (Fig. 1A). This GFP/IVS2–1G3A construct was stably
transfected into CHO cells to create a reporter cell line (CHO-
GFP/IVS2–1G3A). The insertion was directed into a single, pre-
defined locus as previously described (11). A similar cell line,
containing the GFP gene interrupted by a wild-type beta-globin
intron 2 (GFP/IVS2wt), was also made. These CHO-GFP/IVS2wt
cells exhibited high-level GFP expression in 95% of the cells as
observed by FACS and fluorescence microscopy, whereas CHO-
GFP/IVS2–1G3A cells demonstrated undetectable levels of back-
ground fluorescence (data not shown). Southern blots confirmed
the integration of a single copy of the GFP/IVS2 constructs in the
respective cell lines (data not shown).
Bis-PNA Molecules for Targeted Correction of Beta-Globin IVS2–1.
Next, we identified homopurine sequences within the beta-globin
IVS2 that can serve as binding sites for formation of PNA/DNA/
PNA triple helices, based on the strategy that PNA-mediated triplex
formation can stimulate recombination by altering local DNA
topology and triggering DNA repair activity (4, 12). We identified
five such sites within human beta-globin IVS2, ranging from
IVS2–35 (and therefore, 34 base pairs from our mutation site of
interest) to a sequence beginning at IVS2–830 (829 bp from the
IVS2–1 mutation) (Fig. 1B). Bis-PNAs with ethylene glycol-
containing linkers were designed to form PNA/DNA/PNA triplex-
invasion complexes at these sites (Fig. 1C). For the bis-PNAs used
in this study (Fig. 1D), cytosines in the Hoogsteen-bonding PNA
strand were substituted with pseudoisocytosine to eliminate the
requirement for N3 protonation of cytosine, thereby enhancing
complex formation at neutral pH (13). Lysines were also conjugated
to the PNA molecules to increase solubility and to enhance strand
invasion by the molecules (14).
To assess bis-PNA binding to target sites, gel shift assays were
carried out. Increasing concentrations of the various bis-PNAs were
incubated with plasmids containing the relevant PNA binding sites
(Fig. 1E). As shown in Fig. 1E, the PNAs can strand invade into and
bind to their target sites in the plasmid substrate in vitro at
concentrations as low as 200 nM. The multiple bands seen in the gel
shift assay result from structural or stoichiometric isomers formed
by bis-PNAs binding to duplex DNA (15). These isomers are
formed at high PNA concentrations in vitro, but nonetheless
provide evidence of high-affinity binding. PNAs of the reverse
orientation, in contrast, showed no evidence of binding to IVS2
(data not shown).
Induced Genomic Correction at IVS2–1 by PNAs and Donor DNAs. Next,
the ability of bis-PNAs to stimulate gene correction in conjunction
with short (51-mer), single-stranded ‘‘donor’’ oligonucleotides con-
taining the desired reverting sequence change at IVS2–1 was tested
in the CHO-GFP/IVS2–1G3A cell assay (Fig. 2A). The cells were
mock transfected, transfected with IVS2 donor DNA alone, or
Fig. 1. Strategy for targeted correction of beta-globin gene IVS2–1 mutation in mammalian cells. (A) Schematic of the cellular assay, in which intron 2 of the
beta-globingene,mutatedatposition1, interrupts theGFPsequence. Incell linesmadefromthis construct, thismutation leads toanaberrant transcript.GFPexpression
in these cells requires reversion of this IVS2–1 G3A mutation, via PNA-stimulated gene correction, thereby restoring proper splicing. (B) Relative positions and
sequences of the homopurine bis-PNA binding sites in intron 2 of the beta-globin gene. (C) Putative strand invasion complex formed by bis-PNA-35 at the beta-globin
IVS2–35 site, resulting in a PNA/DNA/PNA triplex structure. (D) Sequences of the bis-PNAs used in the current study. The sequence of the 51-mer IVS2 donor DNA
corresponds to the nontemplate strand (single base pair change underlined). J, pseudoisocytidine. (E) Gel shift assays of the bis-PNAs binding to their respective target
sites in a plasmid construct.






transfected with IVS2 donor DNA plus bis-PNAs as indicated.
Because PNAs and DNAs are differentially charged at physiologic
pH, electroporation rather than cationic lipid comixture was chosen
as the method of transfection. The cells were allowed 48 h to
recover, after which they were inspected by fluorescence micros-
copy and analyzed by FACS for GFP expression, indicating cor-
rection at the IVS2–1G3A mutation and expression of a functional
gene product. In initial experiments with asynchronous CHO cells,
overall correction frequencies were low (data not shown). However,
in cells synchronized in S phase, cotransfection of bis-PNA-35 with
the donor DNA yielded correction at this site at an average
frequency of 0.16% (Fig. 2A), more than three times that generated
by transfection of donor DNA alone. Restoration of GFP fluores-
cence in the CHO-GFP/IVS2–1G3A reporter cell line was also
stimulated using bis-PNAs targeting more distant sites in the IVS2
sequence of beta-globin. Bis-PNAs targeting IVS2–64, IVS2–194,
IVS2–512, and IVS2–830 were all able to provoke correction of the
IVS2–1 mutation at frequencies 0.1% (Fig. 2A), indicating that
bis-PNA binding can provoke DNA metabolism over distances of
several hundred base pairs.
As further evidence that proper splicing was restored by PNA-
induced gene correction, we used reverse-transcriptase (RT)-PCR
to analyze RNA extracted from the cells that had acquired GFP
fluorescence after treatment with bis-PNA and IVS2 donor DNA
(Fig. 2B). The GFP-expressing cells were sorted by two rounds of
FACS resulting in a stepwise enrichment of the GFP-positive cell
population. The RT-PCR analysis of the sorted cells (Fig. 2C, lanes
2 and 3) was carried out in comparison with CHO cells containing
the GFP gene with the wild-type beta-globin intron (Fig. 2C, lane
4, WT), and with untreated CHO cells containing the GFP gene
with the mutated intron (Fig. 2C, lane 1, G  A). Note that the
CHO-GFP/IVS2–1G3A cells with the mutant splice site have a
larger RT-PCR product consistent with incorrect splicing (i.e., use
of an aberrant splice site almost 50 nt from the IVS2–1 site). The
CHO-GFP/IVS2wt cells with the wild-type intron yield a smaller
RT-PCR product, indicative of correct splicing out of the entire
intron. The sorted cell populations (Fig. 2C, lanes 2 and 3) show
progressive increases in the proportion of the correct (smaller)
RT-PCR product, in keeping with the restoration of the wild-type
splice site sequence at the IVS2–1 position, and consistent with the
observed, acquired GFP expression by microscopy and FACS. In
addition, genomic DNA was extracted and sequenced from the
sorted GFP-fluorescent cells that had been in culture for 1 month
to demonstrate the presence and persistence of the expected single
base pair change at the genomic level (Fig. 2D).
Treatment of cells with the lysomotropic agent chloroquine has
been reported to enhance transfection of PNAs into cells (16, 17).
Accordingly, we found that chloroquine treatment after electropo-
ration augmented correction frequencies to 0.4%, whereas back-
ground fluorescence in mock-transfected cells did not change,
consistent with an increase in effective delivery of the bis-PNAs and
DNAs (Fig. 3A).
These results were obtained in cells transfected during S phase.
To further explore the cell-cycle dependence of gene correction
induced by bis-PNAs in the CHO-GFP/IVS2–1G3A reporter cells,
we investigated bis-PNA activity in other stages of the cell cycle. We
synchronized cells in various cell cycle stages using established
CHO cell synchronization protocols (18), and transfected cells in
each phase by electroporation, followed by chloroquine treatment.
As shown in Fig. 3B, the introduction of bis-PNAs and IVS2 donor
DNAs into cells synchronized in the G0/G1 or G1 stages stimulates
gene correction at frequencies similar to that provoked by bis-PNA
treatment of an asynchronous population. Compared with frequen-
cies of gene correction in cells in G0, G1, or log-growth phases,
treatment in S-phase cells yields higher levels of PNA-induced gene
correction (Fig. 3B), consistent with previous data on favorable
chromatin accessibility during S phase (18). Treatment of cells
arrested in M phase also resulted in increased gene correction
frequencies, similar to that seen with S phase targeting. This is not
unexpected in light of published work indicating that the disinte-
gration of the nuclear envelope during M phase results in increased
gene transfer efficiencies regardless of transfection method
(19–21).
Targeted Modification at the Endogenous Beta-Globin Locus. We next
sought to extend the results from the GFP reporter system to the
endogenous beta-globin locus using two erythroid cell lines: human
erythroleukemic K562 cells and mouse bone marrow cells contain-
ing the human beta-globin locus (beta-YAC BMCs) (22). We
designed a 50-mer donor oligonucleotide homologous to the human
beta-globin gene, except for a 6-bp change at positions 21–27 of the
donor (corresponding to the last position of exon 2 to 6 of intron
2 of beta-globin) that was designed to abrogate proper splicing of
Fig. 2. bis-PNAs induce correction of the IVS2–1 mutation by donor DNAs in
the CHO-GFP/IVS2–1G3A reporter cell assay. (A) Gene correction was measured
as the percentage of transfected cells expressing GFP by FACS analysis. CHO-
GFP/IVS2–1G3A cells, synchronized in S phase, were transfected with no oli-
gonucleotides (cells), with IVS2 donor DNA (donor alone), or with the indi-
cated bis-PNA plus IVS2 donor DNA. Bar graph represents data collected from
at least three independent experiments, and the error bars indicate standard
errors. (B) Fluorescence micrograph of PNA and donor DNA-treated cells 48 h
after transfection showing GFP-expressing CHO-GFP/IVS2–1G3A cells in a field
of predominantly GFP-negative, uncorrected cells. (C) RT-PCR analysis of RNA
harvested from GFP-positive CHO-GFP/IVS2–1G3A cells that were isolated by
FACS. The IVS2–1 splicing mutation yields a longer RT-PCR product. G  A:
untreated CHO-GFP/IVS2–1G3A cells; S1 and S2: first and second sort, respec-
tively, of CHO-GFP/IVS2–1G3A cells treated with bis-PNA-35 and IVS2 donor
DNA; WT: CHO-GFP/IVS2wt cells with wild-type and thus properly spliced
transcript. Sorted CHO-GFP/IVSG3A cells that were treated with bis-PNA and
IVS2 donor DNA show increasing proportions of RT-PCR product matching
that of CHO-GFP/IVS2wt cells, indicating restoration of correct splicing. (D)
Genomic DNA from sorted GFP-expressing cells maintained in culture for 1
month was harvested and sequenced to verify genomic modification at the
target site. Chromograms are from untreated CHO-GFP/IVS2wt cells containing
the wild-type intron (Top), untreated CHO-GFP/IVS2–1G3A cells with the
IVS2–1 G3A mutation (Middle), and CHO-GFP/IVS2–1G3A cells treated with
bis-PNA-35 and IVS2 donor DNAs, and sorted by FACS for GFP-positive cells
(Bottom).
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the second intron and thereby introduce a thalassemia-like muta-
tion (sequence change shown in Fig. 4A). We found that treatment
of K562 or beta-YAC BMCs with this HBB donor DNA alone does
lead to low-level genomic modification that is specifically detected
by an allele-specific forward primer [Fig. 4B and see supporting
information (SI) Fig. S1 for validation of assay specificity]. As
controls, mock transfected cells show no PCR amplification using
mutant-specific forward primers, indicating a lack of gene modifi-
cation in these cells, whereas the use of wild-type-specific primers
yields amplification products from all treated cell populations as
expected, because only a small proportion of the HBB donor
DNA-treated cells would be predicted to undergo a sequence
change.
Cotransfection of bis-PNA-194 in conjunction with HBB donor
DNA into K562 cells or into beta-YAC BMCs was found to yield
increased genomic modification at the beta-globin locus, compared
with the effect of HBB donor DNA alone, as evidenced by the
increased levels of amplification products using the primers specific
for the introduced mutation (Fig. 4B). The specificity of the
bis-PNA effect was demonstrated by the use of a control bis-PNA
that does not bind the beta-globin gene; when transfected with HBB
donor DNA, this control bis-PNA fails to stimulate gene modifi-
cation beyond that mediated by donor DNA alone (Fig. S1C). We
chose bis-PNA-194 for these studies because it induced the highest
relative frequencies of gene correction in our CHO reporter assay.
The K562 cells were transfected during S phase and treated with
chloroquine posttransfection to enhance oligonucleotide uptake
and delivery, whereas the beta-YAC BMCs were transfected as an
asynchronous population. The PCR-based analysis performed here
is not quantitative in the manner of the FACS analysis of GFP
expression in the CHO reporter cells, however, and so precise
quantitative conclusions cannot be drawn at this point. Nonetheless,
although we cannot assign an absolute value to the frequency of
modification, we can conclude that PNA-stimulated gene targeting
can be achieved at the endogenous beta-globin locus in erythroid
cells.
We then hypothesized that the PNA and HBB donor DNA-
induced 6-bp mutation at the exon 2/intron 2 border would confer
a change in beta-globin mRNA splicing, because the modification
would remove a canonical donor splice site at this position and
might thereby activate downstream, cryptic splice sites. Such aber-
rantly spliced beta-globin mRNAs would therefore retain a portion
of IVS2 sequence. As beta-globin mRNA is undetectable in K562
cells, we used the beta-YAC BMC line previously demonstrated to
follow human adult-pattern globin gene expression and regulation
(22). The beta-YAC BMCs express human wild-type beta-globin
mRNA, as shown by RT-PCR in Fig. 4C (Top). However, we were
able to detect a new species of mRNA in the bis-PNA-194 and HBB
donor treated cells that retained a portion of IVS2, as determined
by use of primers that anneal specifically to the 5 end of IVS2 (Fig.
4C, Bottom). This alternatively spliced beta-globin transcript was
not detected in mock-transfected BMCs, and no amplification was
seen when reverse transcriptase was omitted from the reaction,
indicating that this RT-PCR product did not result from genomic
DNA amplification. These results show that the PNA-stimulated
genomic modification at the IVS2–1 splice site is also detectable at
the transcript level, yielding a variantly spliced beta-globin mRNA
in the beta-YAC BMCs.
For eventual clinical application, primary human hematopoietic
stem and progenitor cells would be the appropriate targets for the
bis-PNA-mediated beta-globin gene correction strategy discussed
here. Therefore, we tested the ability of bis-PNA-194 and HBB
donor DNA to introduce the 6-bp splice site mutation into the
endogenous beta-globin gene of human CD34 progenitor cells,
harvested from peripheral blood in nonthalassemic donors. Less
than 2% of the CD34 cell population expressed mature erythroid
(glycophorin A, CD36), myeloid (CD14, CD15), or megakaryocyte
(CD41) markers at the time of transfection with bis-PNA-194 and
HBB donor DNA (Fig. 4D, Fig. S2, and data not shown). Forty-
eight hours after transfection and growth in cell expansion condi-
tions, the treated CD34 cells were then separated into three pools:
(i) those grown in erythroid differentiation conditions, (ii) those
grown in neutrophil differentiation conditions, or (iii) those har-
vested for genomic DNA analysis. As shown in Fig. 4E, gene
modification can be detected in genomic DNA harvested from
these cells 2 days after transfection with bis-PNA-194 and donor
DNA. Moreover, at 21 days after the single administration of
bis-PNA and donor DNA, when the majority of the cells have
acquired specific lineage markers due to exposure to appropriate
cytokines, the genomic modification is still detectable in the dif-
ferentiated cells (erythroid lineage in Fig. 4E and neutrophil lineage
in Fig. S2). At 21 days posttreatment, the erythroid-differentiated
cells were found to express an aberrant splice form of beta-globin
mRNA, as detected using quantitative RT-PCR with an IVS2-
specific primer (Fig. 4F). Thus, the targeted gene modification was
detected in both erythroid and neutrophil populations derived from
the initial CD34 cells, indicating that bis-PNA and donor DNA
can be used for targeted gene modification in primary human
hematopoietic cells. Because the initially treated CD34 cells were
predominantly a progenitor cell population, and some of the
corrected cells were able to differentiate down the erythroid or
neutrophil pathways, the data presented here suggest that the
genomic DNA of individual myeloerythroid progenitors can un-
dergo targeted modification using this approach. Alternatively, it is
also possible that separate myeloid and erythroid progenitor cells
may have been targeted. Regardless, the results demonstrate that
primary human hematopoietic cells can be modified at the beta-
globin locus by bis-PNAs and donor DNAs, and that the cells can
give rise to differentiated, lineage-specific cell populations. In
addition, the induced gene modification was seen to persist for up
to 3 weeks and yielded a detectable change at the transcript level,
Fig. 3. bis-PNA induction of gene correction at IVS2–1 is enhanced by
chloroquine treatment and is affected by cell cycle phase. (A) CHO-GFP/IVS2–
1G3A cells in S phase were electroporated with bis-PNAs and IVS2 donor DNAs
and treated with or without chloroquine (as indicated) posttransfection. Two
days later, the cells were analyzed by FACS to detect GFP expression, repre-
senting a gene correction event. (B) Cells were transfected with IVS2 donor
DNA and the indicated bis-PNAs during various cell cycle stages (followed by
chloroquine treatment), and then analyzed by FACS as above. Each experi-
ment was performed in triplicate and standard errors are shown.






further suggesting that functional gene modification of human
progenitor cells can be achieved by PNA-mediated targeting.
Discussion
The work reported here demonstrates that triplex-forming bis-
PNAs can stimulate site-specific modification within human beta-
globin gene sequences in mammalian cells, including human he-
matopoietic progenitor cells. In CHO cells carrying a thalassemia-
associated mutation at position IVS2–1, we demonstrate targeted
correction of the mutation at not only the genomic level, but also
the transcript and protein levels. Comparison of cells transfected
with bis-PNAs and donor DNAs while in various phases of the cell
cycle revealed that the highest levels of induced gene correction
were achieved in cells transfected while in S phase. This is consistent
with studies by Majumdar et al., suggesting that the open chromatin
structure in S-phase cells affords increased accessibility of the
chromosomal target site to DNA-binding molecules such as PNAs
and DNA TFOs (18). In addition, unwound duplexes with partial
single-stranded regions (as occur at replication forks) may be
particularly conducive to PNA/DNA/PNA triplex formation by
bis-PNAs. When cell cycle synchronization was also combined with
postelectroporation treatment of cells with chloroquine, correction
frequencies of up to 0.4% were obtained. This enhancement by
chloroquine, which disrupts lysosomes and is thought to thereby
release trapped molecules, indicates that the bioavailability of
transfected PNAs and DNAs is a critical factor.
Targeted gene modification was achieved not only in the reporter
construct in CHO cells but also at the exon 2/intron 2 boundary
within the human beta-globin gene in K562 cells, beta-YAC BMCs,
and human CD34 progenitor cells, in the latter two cases causing
a detectable change in beta-globin splicing. Moreover, we demon-
strate that the PNA-mediated gene modification can persist for at
least a month in the CHO cells and at least 3 weeks in cells derived
from the human CD34 cells. In addition, the PNA- and donor
DNA-modified CD34 cell population was able to give rise to both
erythroid and myeloid lineages in which the beta-globin gene
modification was still detectable. This persistence in CD34-
derived cells supports the feasibility of a transplantation therapy
based on ex vivo treatment of mobilized peripheral blood progenitor
cells in individuals with thalassemia.
Interestingly, bis-PNAs targeting polypurine sites as far away as
830 bp from the IVS2–1 mutation site were effective at stimulating
gene correction by the 51 nt donor DNAs. The ability of triplex-
forming bis-PNAs, and of triplex-forming DNA oligonucleotides
(11), to stimulate recombination with donor DNAs has been shown
to depend, in part, on the nucleotide excision repair pathway (4, 23).
Triplex structures are recognized by the XPA/RPA (24) and
XPC/hRad23 (25) damage recognition complexes, suggesting that
triplexes constitute a helical alteration that can provoke DNA
repair. In the case of the bis-PNAs used here, we tested whether
knockdown of XPA could affect the stimulation of gene modifica-
tion by bis-PNAs. We found that K562 cells, with levels of XPA
reduced by siRNA knockdown, showed lower levels of induced
gene modification in the bis-PNA-194 plus HBB donor DNA
sample (Fig. S3), in concert with our previous mechanistic studies
on triplex-provoked repair. However, the full mechanism(s) by
which triplexes stimulate recombination, and by which they can do
so over distances of several hundred base pairs [as reported here
with bis-PNAs and previously with DNA TFOs (26)] remain to be
elucidated.
Going forward, as evidence accumulates that site-specific gene
targeting can be stimulated in primary human cells, additional
efforts will be needed to optimize techniques to enhance the
targeting of disease-related genes in progenitor cells of various
relevant tissues. We provide important evidence here that human
hematopoietic progenitor cells can be substrates for gene targeting
by PNAs.
Materials and Methods
Oligonucleotides. The sequences of the bis-PNAs used in this study are shown in
Fig. 1D. Bis-PNAs with 8-amino-2,6-dioxaoctanoic acid linkers were either syn-
Fig. 4. PNA-stimulated modification of the endogenous beta-globin gene in human cells. (A) Schematic of bis-PNA-194 designed to bind within intron 2 of the
endogenous beta-globin gene, and of a single-stranded HBB donor DNA molecule designed for modification of the beta-globin gene at the exon 2/intron 2 boundary.
The modification is a 6 nt substitution (underlined) that introduces a splicing mutation in the beta-globin gene. The HBB donor DNA sequence corresponds to the
template strand of the target site. (B) K562 cells synchronized in S phase, or beta-YAC BMCs, were transfected with bis-PNA-194 and HBB donor DNA. Genomic DNAs
from the transfected cells were analyzed by allele-specific PCR to detect the presence of the sequence change introduced by HBB donor DNA. (C) RT-PCR of RNA
harvested from transfected BMCs, using primers that flank the human beta-globin IVS2 region (Upper), or that anneal to the 5 portion of the IVS2 region (Lower).
Beta-YACBMCstreatedwithbis-PNA-194andHBBdonorDNAshowevidenceofbeta-globin transcripts that retainaportionof IVS2; suchtranscriptsareabsent inmock
transfected BMCs. ‘‘No RT’’ indicates the lack of reverse transcriptase enzyme in the RT-PCR. (D) Human CD34 cells were nucleofected (NF) with bis-PNA-194 and HBB
donor DNA and then placed in erythroid-differentiating conditions for up to 21 days. Initially 2% of these NF cells were positive for CD36 or GPA; by 21 days
postnucleofection, 90% of the nucleofected cells were GPA-positive. (E) Genomic DNAs from cells harvested at the indicated times posttransfection were analyzed
by allele-specific PCR to detect the introduced modification in the beta-globin gene. (F) Analysis of RNA prepared from human CD34-derived cells maintained and
differentiated in culture 21 days after transfection of bis-PNA-194 and donor DNA. Quantitative RT-PCR using primers that anneal to the IVS2 sequence reveal the
presence of an aberrant beta-globin transcript in the bis-PNA- and HBB donor DNA-treated cells. Aberrant transcript levels were normalized to total beta-globin
transcript in all samples.
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thesized by us or purchased from Bio-Synthesis (Lewisville TX) or Applied Biosys-
tems (FraminghamMA).Allbis-PNAs,purifiedbyHPLC,hadthreeterminal lysines
on each end except for bis-PNA-512 and bis-PNA-830, which had three lysines
attached to the central linker. Donor oligonucleotides 50 nt and 51 nt in length
were synthesized by Midland Certified Reagent (Midland TX), 5 and 3 end
protected by three phosphorothioate internucleoside linkages at each end and
purified by reversed-phase HPLC.
Electrophoretic Mobility Shift Assays. To test for formation of bis-PNA triplex-
invasion complexes, plasmid DNA engineered to contain the IVS2 sequence (see
SI Methods for plasmid construction) was incubated with increasing concentra-
tions of bis-PNA in TE buffer (pH 7.4) with 10 mM KCl, and digested with flanking
restriction enzymes to release a 110-bp fragment containing the plasmid/bis-
PNA complexes. The products were separated by nondenaturing PAGE and
visualized by silver staining.
Cell Lines. CHO cell lines were generated using the CHO-Flp-In System (Invitro-
gen, Carlsbad CA) to contain a single copy of the EGFP gene, interrupted by the
thalassemic IVS2–1G3A intron or its wild-type equivalent. Refer to SI Methods for
details. The CHO cells were maintained in Ham’s F12 media with 10% fetal bovine
serum (FBS). K562 (American Type Culture Collection CCL-243, Manassas VA) and
beta-YAC BMC (22) cells were maintained in RPMI with 10% FBS. Human CD34
stem and progenitor cells were obtained from granulocyte colony-stimulating
factor (G-CSF)-mobilized peripheral blood of normal healthy donors (Yale Center
of Excellence in Molecular Hematology, Yale University, New Haven, CT), thawed
from cryopreservation and maintained in StemSpan Serum-Free Expansion Me-
dia supplemented with StemSpan CC100 cytokine mixture (StemCell Technolo-
gies, Vancouver, Canada).
Cell Transfection. Cells in 100 l or 250 l of complete media were electroporated
or nucleofected (Amaxa Biosystems, Gaithersburg MD) in the presence of 12 M
donor DNA and 0 or 8 M bis-PNA, as indicated. Electroporation conditions are
provided in SI Methods. Cells were in logarithmic growth or synchronized at
various cell cycle stages using established protocols (see SI Methods) at the time
of transfection. Where indicated, the cells were exposed to 100 M chloroquine
in the media at 4 h after electroporation for a total of 4-h chloroquine treatment.
Forty-eight hours after transfection, cells were collected for genomic DNA and/or
RNA analysis. CD34-derived cells were grown separately in erythroid- or neu-
trophil-differentiating conditions for up to 21 days (see SI Methods for culture
conditions) and harvested for genomic DNA analysis by allele-specific PCR (see
below),or stainedwithPE-orFITC-conjugateantibodiesdirectedagainst lineage-
specific markers for FACS analysis (see SI Methods).
RNA Extraction and RT-PCR. RNA was isolated from CHO cells, beta-YAC BMCs, or
human CD34 cells using the Absolutely RNA Miniprep Kit (Stratagene, La Jolla
CA).TheRNAwastreatedwithDNaseI,andcDNAwasmadeusingtheSuperScript
III RT-PCR kit (Invitrogen). Primers that anneal within the GFP sequence, flanking
the IVS2 sequence, were used for CHO cell RNA analysis. For BMC and CD34 cell
beta-globin RT-PCR, primers were designed to anneal to exon sequences that
flank IVS2. To detect transcripts that retain IVS2, a sense primer annealing to IVS2
sequence was used. RT-PCR reactions that omitted RT enzyme were used as
controls to demonstrate lack of genomic contamination. Quantitative PCR was
performed using Brilliant SYBR Green QPCR on an Mx3000P real-time PCR ma-
chine (Stratagene).
Sequence Analysis of Genomic DNA. Corrected GFP-expressing CHO-GFP/IVS2–
1G3A cells were isolated using a Becton Dickinson FACSVantage SE and main-
tained in F12 media with 10% FBS for 1 month. Genomic DNA was purified using
the Wizard Genomic DNA Purification kit (Promega, Madison WI), and the
GFP-IVS2regionwasamplifiedbyPCRusingprimersthatflanktheIVS2–1site.The
resulting PCR products were gel purified and sequenced.
Allele-Specific PCR. Genomic DNA was harvested from K562 cells, BMCs, or
CD34-derived cells as above. Equal amounts of genomic DNA were subjected to
allele-specific PCR, in which the 3 end of the forward primer corresponds to the
wild type or mutated sequence as introduced by the donor DNA (primer se-
quences and PCR conditions available upon request).
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